Pozen Inc $8.32

down -0.05


27/8/2014 04:00 PM  |  NASDAQ : POZN  
Industries : Drugs / Drug Manufacturers - Other
Get Trend Analysis Icon Get POZN Trend Analysis - it has outperformed the S&P 500 by 41%

Partner Headlines

  1. UPDATE: Ascendiant Capital Markets Upgrades Pozen Following Q2 Results

    Benzinga
  2. Markets Little Changed Ahead Of The Federal Reserve's Policy Decision

    Benzinga
  3. Fed Says Districts Were Optimistic On Economic Outlook; Yahoo! Falls On ...

    Benzinga
  4. Yahoo Falls On Downbeat Results; Time Warner Shares Spike Higher

    Benzinga
  5. Morning Market Losers

    Benzinga
  6. Aura Of Light Shines On Pernix Shares Following Treximet Acquisition

    Benzinga
  7. POZEN Receives CRL From FDA

    Benzinga
  8. Morning Market Losers

    Benzinga
  9. Benzinga's Top #PreMarket Losers

    Benzinga
  10. Pozen Submits Final Study Report for PA8140/PA32540 Phase 1 Study on Schedule

    Benzinga
  11. Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry With The ...

    Benzinga
  12. Will Horizon Pharma Spike Again On Quarterly Report?

    IBD
  13. Morning Market Losers

    Benzinga
  14. Benzinga's Top #PreMarket Losers

    Benzinga
  15. Benzinga's Top Downgrades

    Benzinga
  16. POZEN New PA8140/PA32540 PDUFA Date is April 25, 2014

    Benzinga
  17. POZEN Announces December 31, 2013 as Ex-Dividend Date for Previously Announced ...

    Benzinga
  18. Benzinga's Top #PreMarket Gainers

    Benzinga
  19. POZEN Announces Special Cash Distribution of $1.75/Share

    Benzinga
  20. Horizon to Acquire US Rights for VIMOVO from Pozen

    Benzinga
  21. Benzinga's Top Pre-Market Gainers

    Benzinga
  22. Stocks To Watch For September 5, 2013

    Benzinga
  23. SANOFI

    IBD
  24. Sanofi, Pozen Announce Exclusive License Deal for Commercialization of ...

    Benzinga
  25. Pozen Inc. Reports Operating Results (10-Q)

    GuruFocus
  26. UPDATE: Ascendiant Capital Markets Initiates POZEN at Buy; Future Royalties ...

    Benzinga
  27. POZEN Announces PA32540 Provides Superior Antiplatlet Effects over a Standard ...

    Benzinga
  28. POZEN Provides Positive Update on Its PA Program and Results of Its Type ...

    Benzinga
  29. POZEN Receives Patent on PA Products for Treatment of Cardiovascular Disease ...

    Benzinga
  30. Celgene, Bed Bath & Beyond Among Stocks Gapping Down Thursday

    FoxBusiness
  31. Morning Market Losers

    Benzinga
  32. POZEN Says FDA Does Not Agree That BioEquivalence Was Demonstrated

    Benzinga
  33. POZEN Announces Licensing Deal with Desitin Arzneimittel GMBH for MT 4 ...

    Benzinga
Trading Center